55461. 26. Bucci B, D’Agnano I, Botti C, Mottolese M, Carico E, Zupi G, Vecchione A: EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res 1997, 17:76974. 27. LeMaistre CF, Meneghetti C, Howes L, Osborne CK: Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 1994, 32:9703. 28. Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial development aspect expression with tumor angiogenesis and with early relapse in key breast cancer. Gan 1994, 85:1045049. 29. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, et al: ZD6474 inhibits vascular endothelial growth aspect signaling, angiogenesis, and tumor development following oral administration. Cancer Res 2002, 62:4645655. 30. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G: Antitumor effects of ZD6474, a little molecule vascular endothelial development factor receptor tyrosine kinase inhibitor, with additional activity against epidermal development factor receptor tyrosine kinase.Linaclotide Clin Cancer Res 2003, 9:1546556. 31. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M: ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010, 9:59203.32. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K: Smaller in-frame deletion inside the epidermal growth element receptor as a target for ZD6474. Cancer Res 2004, 64:9101104. 33. Rustogi A, Budrukkar A, Dinshaw K, Jalali R: Management of locally advanced breast cancer: evolution and present practice. J Cancer Res T 2005, 1:210. 34. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG: Higher tumor levels of vascular endothelial development aspect predict poor response to systemic therapy in sophisticated breast cancer. Cancer res 2001, 61:5407414. 35. Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D, Brankovic-Magic M, Kanjer K, Gavrilovic D, Mitrovic L, Borojevic N, Vukotic D, Spuzic I: Expression of epidermal development factor receptor in breast cancer, from early stages to sophisticated illness. J Exp Clin Cancer Res 1999, 18:34755. 36. Dunkern TR, Fritz G, Kaina B: Ultraviolet light-induced DNA damage triggers apoptosis in nucleotide excision repair-deficient cells through Bcl-2 decline and caspase-3/-8 activation.Dehydroabietic acid Oncogene 2001, 20:6026038. 37. Kulms D, Poppelmann B, Yarosh D, Luger TA, Krutmann J, Schwarz T: Nuclear and cell membrane effects contribute independently to the induction of apoptosis in human cells exposed to UVB radiation.PMID:23695992 Proc Natl Acad Sci U S A 1999, 96:7974979. 38. Murahashi H, Azuma H, Zamzami N, Furuya KJ, Ikebuchi K, Yamaguchi M, Yamada Y, Sato N, Fujihara M, Kroemer G, Ikeda H: Attainable contribution of apoptosis-inducing element (AIF) and reactive oxygen species (ROS) to UVB-induced caspase-independent cell death inside the T cell line Jurkat. J Leukoc Biol 2003, 73:39906. 39. Maeda T, Chua PP, Chong MT, Sim AB, Nikaido O, Tron VA: Nucleotide excision repair genes are upregulated by low-dose artificial ultraviolet B: proof of a photoprotective SOS response J Invest Dermatol 2001, 117:1490497. 40. Owen JB, Coia LR, Hanks GE: Current patterns of growth in radiation therapy facilities inside the United states of america: a patterns of care study report. Int J Radiat Oncol Biol.